Institute for Applied Cancer Science
MD Anderson is known for providing cancer patients with exceptional care, which includes early access to innovative new treatments through clinical trials. The Institute for Applied Cancer Science (IACS) is a new hybrid model that uniquely combines the drug discovery capabilities of the biopharmaceutical industry and the extensive knowledge of biology found in academia with the expertise of MD Anderson's top clinicians to develop new therapeutic options.
IACS has the singular goal of rapidly developing novel, effective and safe therapeutics that improve patient health. Close collaborations with the physician scientists here at MD Anderson helps to position these therapeutics to benefit specific patient populations with unmet medical need.
IACS executes programs with the highest probability of clinical success in a rigorous, goal-oriented, data-driven manner. Employing the Bench at the Bedside approach IACS uniquely integrates three key components:
• Access to insights gained from the largest set of cancer patients and some of the best physician scientists in the nation
• Highly experienced team of drug discovery and development scientists
• Clinically informed, patient-oriented research focused on the endpoint of delivering impactful clinical responses